Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Inclusion Criteria:

* Age \>= 18 years
* Participated in and completed a previous Tanespimycin protocol without evidence of unacceptable toxicity and is deemed by the Investigator to be deriving benefit from the Tanespimycin drug as defined in the previous protocol
* All patients must rollover to this continuation protocol within 30 days of the last dose of Tanespimycin in the previous protocol, unless previously approved by the Medical Monitor
* All Adverse Events from the prior protocol, must have resolved to NCI CTCAE (v. 3.0) Grade \<= 2
* The following laboratory results, within 10 days of Tanespimycin administration:
* Hemoglobin \>= 8 g/dL
* Absolute neutrophils count \>= 1.0x 10\*9\* /L
* Platelet count \>= 50 x 10\*9\* /L
* Serum bilirubin \<= 2 x ULN
* AST \<= 2.5 ULN
* Serum creatinine \<= 2 x ULN
* ECOG performance status of 0, 1 or 2
* Signed informed consent

Exclusion Criteria:

* Pre-existing neuropathy of CTCAE Grade \>= 3 due to any cause
* Documented hypersensitivity reaction of CTCAE Grade \>= 3 to prior therapy containing Cremophor (for those patients receiving Tanespimycin Injection)
* Pregnant or breast-feeding women
* Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic), excluding Tanespimycin within 21 days prior to receipt of study medication
* Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient